Introduction: It remains unclear if tau imaging may assist diagnosis of chronic traumatic
encephalopathy (CTE). Flortaucipir PET has shown superior frontal with medial temporal tau …

Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease (…

Background: In Alzheimer’s disease, heterogeneity has been observed in the postmortem
distribution of tau neurofibrillary tangles. Visualizing the topography of tau in vivo may facilitate …

A neuroinflammatory reaction in Alzheimer disease (AD) brains involves reactive astrocytes
that overexpress monoamine oxidase-B (MAO-B). F-(S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-…

Reactive gliosis, characterized by reactive astrocytes and activated microglia, contributes
greatly to neurodegeneration throughout the course of Alzheimer disease (AD). Reactive …

Introduction We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at
aa217 enhanced by additional p‐tau sites (p217+tau). Methods Plasma p217+tau levels were …

Background Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−)
occurs with aging. The tau PET tracer 18 F-MK6240 has low non-specific background …

Background and Objectives Traumatic brain injury (TBI) has been promoted as a risk factor
for Alzheimer disease (AD). There is evidence of elevated β-amyloid (Aβ) and tau, the …

Purpose Previous studies have shown that Aβ-amyloid (Aβ) likely promotes tau to spread
beyond the medial temporal lobe. However, the Aβ levels necessary for tau to spread in the …

Background: Astrocyte reactivity is an early event along the Alzheimer’s disease (AD)
continuum. Plasma glial fibrillary acidic protein (GFAP), posited to reflect astrocyte reactivity, is …